Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ
in subjects with moderately to severely active RA who have responded inadequately to MTX. The
primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease
activity and improve physical function. The study is expected to provide safety information
in a large group of subjects over at least a 24 week period. Adalimumab 40 mg q2w SC has been
included as the active comparator for assay sensitivity and non inferiority evaluations.

Inclusion Criteria:

- Subjects willing and able to sign informed consent

- Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised
classification criteria for RA for at least 12 weeks prior to Screening.

- Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at
a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses)

- The dose and means of administering MTX must have been stable for at least 6 weeks
prior to Screening.

- Subjects must be willing to take folic acid or equivalent throughout the study.

- Subjects must have moderately to severely active RA disease as defined by all of the
following:

- ≥6 tender joints (68 joint count) at Screening and baseline; and

- ≥6 swollen joints (66 joint count) at Screening and baseline; and

- CRP above ULN at Screening based on the central laboratory results

Exclusion Criteria:

- Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,
gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile
idiopathic arthritis, or systemic lupus erythematosus)

- Prior exposure to any licensed or investigational compound directly or indirectly
targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen
tyrosine kinase [SYK] inhibitors)

- Prior treatment with cell depleting therapies including anti CD20 or investigational
agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19)

- Prior use of bDMARDs

- Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or
change in dosage within 2 weeks prior to baseline

- Prior history of no response to hydroxychloroquine and sulfasalazine

- Prior use of cDMARDs (other than MTX) within the following windows prior to baseline
(cDMARDs should not be discontinued to facilitate a subject's participation in the
study, but should instead have been previously discontinued as part of a subject's
medical management of RA):

1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,
chloroquine, gold, penicillamine, minocycline, or doxycycline

2. 12 weeks for leflunomide unless the subject has completed the following
elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a
dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a
dosage of 50 grams 4 times daily for at least 24 hours

3. 24 weeks for cyclophosphamide

- Participation in any other investigational drug study within 30 days or 5 times the
terminal half-life of the investigational drug, whichever is longer, prior to baseline

- Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to
baseline

- Abnormal laboratory values

- Subjects with concurrent acute or chronic viral hepatitis B or C infection

- Subjects with HIV infection

- Subjects with:

1. Current active TB disease or a history of active TB disease.

2. Close contact with an individual with active TB within 1.5 years prior to
Screening

3. History of untreated latent TB infection (LTBI), regardless of IGRA result at
Screening

4. Positive interferon-gamma release assay (IGRA) result at Screening. If
indeterminate, the IGRA can be repeated once during the Screening Period. If
there is a second indeterminate result, the subject will be excluded.

- Concurrent malignancy or a history of malignancy within the last 5 years

- Uncontrolled diabetes mellitus

- History of chronic alcohol or drug abuse as judged by the Investigator

- Female subjects who are pregnant, currently lactating

- Female subjects of childbearing potential who are not willing to use a highly
effective method of contraception during the study OR Male subjects with partners of
childbearing potential not willing to use a highly effective method of contraception
during the study

- Subjects with a known hypersensitivity to any component of the OKZ drug product,
adalimumab, or placebo

- Other exclusion criteria may apply